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IMATINIB RESISTANCE IN PHILADELPHIA 
CHROMOSOME-POSITIVE CHRONIC MYELOID 
LEUKEMIA 
Rivky Kops 
Chronic myeloid leukemia (CML) is a disorder of blood stem cells in bone 
marrow, which leads to a rapid production of white blood cells. Of the patients 
diagnosed with CML, 95% have the Philadelphia (Ph) chromosome, which means that 
chromosome 22 is smaller than regular (22 q-).  Historically, the median survival time 
for chronic phase CML patients was four to five years, while the accelerated and blast 
(profusion of immature red blood cells in circulation) phases had a much shorter 
survival time.  Recently, due to the revolutionary new drug imatinib, CML patients 
diagnosed early have a higher survival rate.  Nevertheless, some patients may show 
resistance to imatinib, and alternative treatments must be considered (Hochhaus and 
La Rosée 2004).   
CHRONIC MYELOID LEUKEMIA 
Chronic myeloid leukemia originates in a single pluripotent bone marrow stem 
cell.  It accounts for approximately 15% of all leukemia cases (Liesveld and Lichtman 
2011).  As shown in Figure 1 below, the long (“q”) arms of chromosome 9 and 22 swap 
DNA, resulting in a longer chromosome 9 (9q+) and shorter chromosome 22 (22q-). 
Chromosome 22q- is known as the Philadelphia chromosome and is the 
identifying characteristic of CML in over 90% of cases.  It occurs when the Abelson 
oncogene (ABL) of chromosome 9 at 9q34 fuses with the breakpoint cluster region 
(BCR) of chromosome 22 at 22q11.  BCR is a multiplier gene, and ABL codes for a 
tyrosine kinase which is heavily suppressed in healthy cells (Encyclopedia of the 
Human Genome).  The resulting BCR-ABL gene codes for a constitutively active 
tyrosine kinase which induces rapid stem cell differentiation by inducing cell growth 
and bypassing signals that block cell mitosis.  These new BCR-ABL+ stem cells have 
Figure 1: Normal chromosomes 9 and 22, and 9q+ and 22q- resulting 
from the reciprocal BCR-ABL translocation. Source: Litzow 2006 
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lower proliferation capacities compared to normal stem cells, but the tremendous 
increase in stem cells results in a net increase in leukocytes .  Granulocytes, and often 
megakaryocytes, are the main cells arising from the malignant stem cells.  However, 
studies have also found erythroblasts and macrophages with the Philadelphia 
chromosome, leading to the belief that CML arises in a pluripotent stem cell (Liesveld 
and Lichtman 2011).   
Early stage chronic myeloid leukemia is asymptomatic; the abnormally high 
percentage of white blood cells compared to red blood cells is frequently only detected 
as part of a routine complete blood count. Common CML symptoms are anemia; 
extreme blood granulocytosis; splenomegaly; early satiety and unintentional weight 
loss; and, seldom, thrombocytosis.  A chronic phase is usually followed by an 
accelerated phase, which is characterized by blasts making up 15% of the red blood 
cells circulating in the bloodstream.  Historically, median survival rate in the 
accelerated phase has been one to two years, with many dying before reaching blast 
crisis.  Blast phase, characterized by 30% immature cells, had a median survival of 
three to six months.  Ninety percent of patients are diagnosed in the chronic stage. In 
the chronic stage, survival rates and remission rates are more optimistic compared to 
the accelerated and blast phases (Pemmaraju et al. 2011). 
There are three markers of remission: hematological, cytogenetic, and 
molecular response.  Complete hematological remission is marked by white blood cell 
counts returning to normal levels of less than 10 x 109/L and the disappearance of 
CML symptoms.  However, while quality of life is much improved with the 
normalization of white blood cell counts, hematological remission is a poor indicator of 
long-term survival.  Cytogenetic response means that cells bearing the Ph chromosome 
are not being produced.  Partial cytogenetic response is defined as 1 to 35% of 
metaphases remaining Ph positive, while complete cytogenetic response means that no 
mature cells bear the Ph chromosome.  Complete molecular response means that there 
are no detectable BCR-ABL transcripts (Pemmaraju et al. 2011).  In an IRIS 
(International Randomized Study of Interferon and STI-571) trial, which compared 
the efficacy of drugs targeting CML, achieving a complete cytogenetic response was 
determined to be the most important factor in long-term survival.  Of the patients 
achieving complete cytogenetic response but incomplete molecular response, the five-
year survival rate was 98% (Wetzler et al. 2012).  Therefore, achieving a complete 
cytogenetic response was established as the goal of treatment (Pemmaraju et al. 2011).  
Progression-free survival, which means that patients have not progressed from the 
chronic phase to a more advanced state, is also used as a benchmark of successful 
therapy, since patients in the chronic phase usually experience few side effects and 
have a higher quality of life. 
Because the vast majority of CML patients display the Ph chromosome, the 
BCR-ABL fusion is the best target for therapy to treat CML.  Imatinib is the first truly 
targeted drug to inhibit a tyrosine kinase (Marx 2001), and it has granted CML 
patients a hopeful prognosis. 
IMATINIB 
Imatinib, a highly targeted tyrosine kinase inhibitor, uses hydrogen bonding to 
bind to the contact site in the inactive configuration of the BCR-ABL kinase. This 
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hinders the ATP binding site so that the affected cell has no source of energy for 
proliferation and survival. This process is shown in Figure 2. 
Imatinib also induces apoptosis in 
Philadelphia-chromosome-positive cells without 
affecting Ph negative cells (Moen et al. 2007).  It has 
a very high success rate, and patients diagnosed in the 
early chronic phase now have an estimated survival of 
20 to 30 years.  The rate of complete cytogenetic 
response for early chronic phase is about 80%, and 
five-year progression-free survival is 96.7%.  Imatinib 
is well tolerated, with less than 3% of patients 
showing resistance to it (Pemmaraju et al. 2011).  The 
structure of imatinib is shown in Figure 3. 
Prior to the introduction of imatinib, patients were treated with interferon 
(IFN-#), which treated CML more effectively than standard chemotherapy.  IFN-# 
was successful in achieving a complete cytogenetic response in 5 to 25% of patients.  
Combining IFN-# with cytarabine yielded better results and a greater probability of 
survival.  In an IRIS trial, patients were randomly chosen for either IFN-# with 
cytarabine or imatinib.  Imatinib showed significantly higher rates of complete 
cytogenetic response and lower toxicity levels than IFN-# with cytarabine.  At 19 
months, the percent of imatinib-treated patients achieving complete cytogenetic 
remission was 79%, compared to 11% achieved in patients treated with IFN-# with 
cytarabine. At the five-year follow-up, the percent of complete cytogenetic remission 
from imatinib had increased to 82%. There are no five-year follow-up data for the 
group taking IFN-# because most of that group switched to imatinib treatment.  
Additionally, health-related quality of life was maintained among the patients on 
imatinib, while those receiving IFN-# with cytarabine experienced a deterioration in 
Figure 2: Imatinib (STI571) filling ATP binding site of BCR-ABL tyrosine kinase. Source: Feng 
et al. 2010 
 
Figure 3: Structure of imatinib. 
Source: Chabner et al. 2011. 
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quality of life.  Imatinib was therefore established as the primary therapy for chronic 
myeloid leukemia (Moen et al. 2007). 
The standard dose for imatinib is 400 mg/day, with doses under 300 mg/day 
yielding unsatisfactory results.  The TOPS (Tyrosine Kinase Inhibitor Optimization 
and Selectivity) trial investigated the possible benefit of doubling imatinib dose to 800 
mg/day.  While patients taking 800 mg/day initially fared better, the percentages of 
complete cytogenetic responses over a longer period were nearly equal: 64% for 800 
mg/day and 58% for 400 mg/day. Since long-term toxicity levels have not been 
assessed for the higher dose, the standard dose is currently 400 mg/day (Pemmaraju et 
al. 2011). 
Imatinib, unlike previous treatments for CML, is unique in that it can effect a 
hematological remission for patients in the accelerated and blast phases (Marx 2001). 
However, 4-5% of patients on imatinib, particularly those who have progressed past 
the chronic stage, become resistant to the drug and relapse (Biotech Business Week 
2006), including 80% of patients in blast crisis (Marx 2001).  Others may never 
achieve remission with imatinib. 
IMATINIB RESISTANCE 
Imatinib resistance results from BCR-ABL gene amplification and point 
mutations.  Some causes of resistance can be countered by dose escalation, while 
others render imatinib useless. 
Some patients relapse due to gene amplification, which leads to increased 
kinase activity.  The BCR-ABL gene produces more tyrosine kinase than standard 
dose imatinib (400 mg/day) can counter.  The tyrosine kinase produced by BCR-ABL 
overexpression causes too many leukemia cells to be produced. While imatinib still 
functions properly, the leukemia cells proliferate at an even faster rate than usual.  If 
the patient has not become imatinib resistant, an increased dosage of 600 or 800 
mg/day may overcome the rapid proliferation of cells and bring about a remission.  In 
particular, patients who achieved a complete cytogenetic remission and then lost the 
remission benefit from increased dosage (Pemmaraju et al. 2011). 
Some patients are completely resistant to imatinib. Imatinib resistance is 
categorized as either primary or acquired.  Primary resistance means that the patient 
never responds to the medication.  Acquired resistance means a loss of imatinib-benefit 
after previously benefiting from it, which can be on a hematological, cytogenetic, or 
molecular level (Hochhaus and La Rosée 2004). 
Point mutations, individual changes in gene sequencing, often confer drug 
resistance. They are thought to occur due to the inherent genetic instability of 
cancerous cells (Marx 2001). The dominant mechanism of imatinib resistance is 
genetic mutation in the kinase domain (ABL portion) of BCR-ABL.  The mutated Ph 
chromosome contains an amino acid residue different than the regular BCR-ABL 
oncogene, coding for a slightly different tyrosine kinase.  Since imatinib competitively 
inhibits the BCR-ABL tyrosine kinase by snugly fitting into the contact site, any 
change in the binding site can prevent it from binding effectively.  Additionally, 
mutations often lock the protein in its active configuration, and imatinib binds only to 
the inactive configuration.  Imatinib’s pronounced specificity in binding makes 
resistance common (Liesveld and Lichtman 2011).  
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There are four main regions of the protein that are prone to resistance-
conferring mutations:  the ATP binding loop, or P-loop; the imatinib contact site; the 
catalytic domain; and the activation loop, which controls catalytic activity and changes 
conformation depending on protein activation (Litzow 2006).  Although over 40 point 
mutations have been identified, 85% of mutations occur at seven amino acid residues: 
M244V, G250E, Y253F/H, and E255K/V in the P-loop; T315I at the contact site; 
M351T and F359V in the catalytic domain (Cang and Liu 2008).  Usually only a single 
point mutation is detected in an imatinib-resistant patient, but occasionally patients 
have multiple mutations (Hochhaus and La Rosée 2004).  
P-loop mutations account for 36-48% of all mutations (Cang and Liu 2008).  
The tyrosine kinase is composed of two flexible loops: the P-loop and the activation 
loop (An et al. 2010).  When a mutation occurs in the P-loop, the configuration 
changes, causing the activation loop to fold outward into the active configuration and 
remain that way.  Imatinib binds only to the inactive form of BCR-ABL and is, 
therefore, ineffective against most forms of P-loop mutations (Litzow 2006). 
Contact site mutations confer high levels of resistance as well.  The 315th amino 
acid of the tyrosine kinase serves as a contact point for imatinib.  The threonine 
present at 315 forms a hydrogen bond with imatinib, a step that is crucial in order for 
imatinib to fill the ATP binding pocket (Hochhaus and La Rosée 2004).  The switch of 
threonine to an isoleucine residue confers resistance in two ways.  First, isoleucine 
does not form a hydrogen bond with imatinib like threonine does, so imatinib cannot 
form the bond critical for the drug’s inhibitory effect on tyrosine kinase.  Second, 
isoleucine is bulkier than threonine, so it acts as a “gatekeeper” by adding residue to 
the contact site, sterically hindering imatinib (Tanaka et al. 2010).  In fact, the T315I 
mutation confers resistance to all second-generation tyrosine kinase inhibitors as well, 
as will be expounded upon later.  
According to the MD Anderson algorithm for treating CML, if a patient has 
not achieved a complete hematological response within three months from the start of 
treatment, the patient is deemed imatinib resistant and switched to a different 
treatment method.  Likewise, a patient who has not achieved a complete cytogenetic 
remission at 18 months is switched to a different therapy.  If at any point in imatinib 
treatment, a patient relapses and loses a level of remission, it indicates a need for 
alternative treatment (Pemmaraju et al. 2011).  The MD Anderson algorithm for CML 
treatment is shown in Figure 4. 
ALTERNATIVES 
Several alternative forms of treatment have been suggested for patients not 
responding satisfactorily to imatinib.  They include allogeneic stem cell transplantation, 
novel tyrosine kinase inhibitors, aurora kinase inhibitors, and reactive oxygen species 
generators. 
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Allogeneic stem cell transplantation (SCT) is currently the only potentially 
curative treatment for CML (Linker and Damon 2011).  All other therapies control 
the BCR-ABL oncogene expression; allogeneic SCT destroys the stem cells bearing 
the gene (Pemmaraju et al. 2011).  SCT involves heavy chemotherapy and/or radiation 
regimens to destroy the diseased cells, ridding the body of the disease, and the 
transplant of healthy stem cells to the patient’s bone marrow to replenish the cells 
destroyed by chemotherapy.  Autologous SCT, in which healthy stem cells are 
extracted from the patient prior to chemotherapy and reintroduced afterwards, is 
sometimes used (Liesveld and Lichtman 2011).  However, autologous SCT is 
associated with high morbidity levels due to the high-dose chemotherapy preparatory 
regimen.  Allogeneic SCT uses stem cells from a well-matched donor which are infused 
Figure 4: The MD Anderson algorithm for treatment of CML. Patients who fail to achieve the desired 
remission level within the specified timeframe or relapse are switched to a different therapy. Source: 
Pemmaraju et al. 2011 
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with mature donor leukocytes.  This is more effective than autologous SCT because 
the grafted leukocytes recognize any remaining cancerous stem cells as foreign and 
attack them.  This graft-versus-malignancy effect successfully eradicates malignant 
stem cells not destroyed by the preparatory regimen.  Therefore, the pre-transplant 
regimen does not need to be as rigorous, making allogeneic SCT therapy an option for 
older patients (ages 60-75) who cannot tolerate standard high-dose chemotherapy 
(Linker and Damon 2011).  Prior to the introduction of imatinib, allogeneic SCT was 
the treatment of choice for younger patients with a well-matched donor.  However, 
allogeneic SCT has high morbidity levels due to incidence of graft-versus-host, in 
which the donor’s cells attack the host.  Therefore, with the introduction of imatinib, 
allogeneic SCT is no longer first-line therapy for chronic phase CML.  However, it still 
remains useful for treating patients with poor response to imatinib and in patients with 
the T315I mutation (Liesveld and Lichtman 2011). 
Following the success, and mindful of the flaws, of imatinib, several second-
generation tyrosine kinase inhibitors (TKI) were created.  These TKIs counter 
different imatinib resistance-conferring mutations.  The three second-generation TKIs 
that are currently available are dasatinib, nilotinib, and bosutinib.  Each has a distinct 
advantage over imatinib. 
Dasatinib is a powerful TKI that inhibits many tyrosine kinases.  It exhibits 300 
times greater potency against the unmutated form of BCR-ABL than imatinib.  Unlike 
imatinib, it binds to both the active and inactive forms of BCR-ABL and is, thus, 
unaffected by P-loop mutations (Cang and Liu 2008).  Although effective against most 
mutations, it is ineffective against T315I, V299L, F317L, and a few others.  Dasatinib 
has impressive results; over 50% of patients in chronic phase who failed imatinib 
therapy achieved a complete cytogenetic response with dasatinib.  The standard dose 
for dasatinib is 100 mg daily, based on minimal toxicity levels and maximum 
performance.  Dasatinib has few side effects and is overall well tolerated (Pemmaraju 
et al. 2011).   
Based on dasatinib’s effectiveness 
against imatinib-resistant CML, a study 
was conducted using dasatinib as front-line 
therapy in newly diagnosed chronic phase 
CML.  Results were impressive and swift.  
Within six months, 90% of patients 
achieved complete cytogenetic remission 
(compared to historical records of (80% 
with imatinib); within 12 months, 45% of 
patients had further improved to major 
molecular remission; and within 24 months, 71% achieved major molecular remission 
(Pemmaraju et al. 2011).  The structure of dasatinib is shown in Figure 5. 
Nilotinib is structurally similar to imatinib but modified to increase drug 
potency and selectivity.  Like imatinib, it binds to the inactive configuration of BCR-
ABL, locking the activation loop in the closed form to block the ATP binding site.  
Unlike imatinib, however, nilotinib forms hydrogen bonds with the amino acids at 286 
and 381, two residues not prone to mutation (Chabner et. al. 2011).  In a study of 321 
chronic phase CML patients who failed imatinib treatment, 46% achieved a complete 
cytogenetic response with nilotinib.  Nilotinib has an advantage over imatinib because 
Figure 5: Molecular formula for dasatinib.  
Dasatinib binds both the active and inactive 
configurations of ABL-BCR tyrosine kinase. 
Source: Chabner et al. 2011 
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it is effective against nearly all mutations, with the exception of T315I (Pemmaraju et 
al. 2011).  Some P-loop mutations have shown in-vitro resistance to nilotinib, so 
patients with P-loop mutations might benefit more from dasatinib (Cang and Liu 
2008).  Nilotinib is approved at 400 mg twice daily and is well tolerated (Pemmaraju et 
al. 2011). 
Due to nilotinib’s high success rate in 
imatinib-resistant patients, studies were conducted 
using nilotinib as the initial therapy for early chronic 
phase CML.  Over 90% of patients achieved a 
complete cytogenetic response within six months, 
and an astounding near 80% of patients achieved a 
major molecular remission by 12 months.  More 
significantly, one study showed that by 12 months, 
less than 1% of patients had progressed to the 
accelerated or blast phases, compared to 4% in 
patients receiving imatinib (Pemmaraju et al. 2011).  
The structure of nilotinib is shown in Figure 6. 
Bosutinib is another potent TKI currently in 
development.  It is 30-50 times stronger than 
imatinib against unmutated CML and is active 
against almost all BCR-ABL mutations.  Bosutinib has success rates similar to the 
other second-generation TKIs; over 40% of chronic phase CML patients who switch to 
bosutinib because of imatinib resistance achieve a complete cytogenetic response.  
Bosutinib has an advantage over other TKIs due to its greater selectivity.  Unlike the 
other TKIs, bosutinib has less off-target outcomes, which is theorized to reduce 
toxicity associated with other TKIs.  Unfortunately, though, as with the other TKIs, 
bosutinib is ineffective against the T315I mutation (Cang and Liu 2008). 
The efficacies of the three second-generation TKI’s, dasatinib, nilotinib, and 
bosutinib, are summarized in Table 1. 
Despite the efficacy of second-generation TKIs, none are successful in 
combating the T315I, and alternate therapies are necessary. 
Aurora kinase inhibitors are a new class of CML therapy.  Aurora kinases have 
been implicated in intensifying certain cancers, so combatting aurora kinases with 
aurora kinase inhibitors holds promise for controlling CML (Tanaka et al. 2010).  
MK-0457 was the first aurora kinase inhibitor to show activity against T315I.  It binds 
to the amino acid at 381, and not at 315, thereby avoiding the steric clash with 
isoleucine (Quintas-Cardama and Cortes 2008).  However, despite the promising 
results of MK-0457, trials were stopped due to concerns of cardiotoxicity (Cang and 
Liu 2008).  Other aurora kinase inhibitors, like XL228, PHA-739358, KW-2449, and 
AT9238, are in various stages of clinical trials (Quintas-Cardama and Cortes 2008).  
Though the introduction of aurora kinase inhibitors in T315I+ CML is recent, results 
of early trials look promising since aurora kinase inhibitors do not bind to T315 and, 
therefore, are unhindered by isoleucine. 
Another alternative for imatinib- and TKI-resistant CML is the use of reactive 
oxygen species (ROS).  ROS are the main catalysts of redox dysregulation and 
oxidative stress within cells, especially cancerous cells (Wondrak 2009).  The BCR- 
 
 
 
Figure 6: Molecular structure of 
nilotinib. Like imatinib, nilotinib 
binds only the inactive conformation 
of the BCR-ABL protein. Source: 
Chabner et al. 2011 
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Table 1: Response to Second-Generation TKI’s 
PERCENT RESPONSE 
  Dasatinib  Nilotinib  Bosutinib  
  C
P 
A
P 
M
yBP 
L
yBP 
C
P 
A
P 
M
yBP 
L
yBP 
C
P 
A
P 
B
P 
  N
=387 
N
=174 
N
=109 
N
=48 
N
=321 
N
=137 
N
=105 
N
=31 
N
=146 
N
=51 
N
=38 
Median 
follow-up 
(mo) 
1
5 
1
4 
1
2 
1
2 
2
4 
9 3 3 7 6 3 
% Resistant 
to imatinib 
7
4 
9
3 
9
1 
8
8 
7
0 
8
0 
8
2 
8
2 
6
9 
N
R 
N
R 
% 
Hematologi
c Response 
  7
9 
5
0 
4
0 
9
4 
5
6 
2
2 
1
9 
8
5 
5
4 
3
6 
CHR 9
1 
4
5 
2
7 
2
9 
7
6 
3
1 
1
1 
1
3 
8
1 
5
4 
3
6 
% 
Cytogenetic 
Response 
N
R 
4
4 
3
6 
5
2 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Complete 4
9 
3
2 
2
6 
4
6 
4
6 
2
0 
2
9 
3
2 
3
4 
2
7 
3
5 
Partial 1
1 
7 7 6 1
5 
1
2 
1
0 
1
6 
1
3 
2
0 
1
8 
% Survival 
(at 12 
months) 
9
6 (15) 
8
2 (12) 
5
0 (12) 
5
0 (5) 
8
7 (24) 
6
7 (24) 
4
2 (12) 
4
2 
(12) 
9
8 (12) 
6
0 
(12) 
5
0 
(10) 
CP, chronic phase; AP, accelerated phase; BP, blast phase; MyBP, myeloid blast phase; LyBP, 
lymphoid blast phase; NR, not reported.                                         Source: Pemmaraju et al. 2011 
ABL oncogene promotes ROS-generated redox imbalances, and this 
dysregulation can be manipulated to induce cell death.  The introduction of exogenous 
ROS-generating species increases oxidative stress in cancerous cells, leading to rapid 
protein degradation and cell death (Zhang et al. 2008).  Redox imbalances operate 
under synthetic lethality, which means that only cancerous cells are killed, not normal 
cells (Wondrak 2009).  PEITC (&-phenylethylisothiocyanate) is a naturally-occurring 
ROS-generating agent.  In one experiment, when introduced in cells bearing normal 
BCR-ABL and cells with the T315I mutation, PEITC completely inhibited cell 
growth, raised oxidative levels twofold, and caused over 60% cell death (Zhang et al. 
2008).  The viability of ROS-generating agents like PEITC in vivo has not yet been 
established, but early research shows promise (Wondrak 2009). 
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SUMMARY 
Chronic myeloid leukemia is no longer as frightening a diagnosis as cancer can 
be.  The historic median survival of 4-5 years is a thing of the past.  Novel targeted 
drugs can restrain BCR-ABL+ stem cells to the point that the disease is virtually 
undetectable.  Imatinib, the first molecularly targeted anticancer therapy, is so 
effective that over 95% of patients maintain progression-free survival at five years.  
Even the few patients who are resistant to imatinib are not left without hope.  
Allogeneic stem cell transplants can cure the disease in healthy patients with a well-
matched donor.  Second-generation tyrosine kinase inhibitors can effect remission in 
most patients bearing imatinib-resistant BCR-ABL mutations.  Dasatinib, nilotinib, 
and bosutinib are second-generation TKIs with differing potentials against the 
different mutations.  Though none of these TKIs can counter the T315I contact site 
mutation, other therapies can.  Aurora kinase inhibitors and ROS-generating agents 
are in various stages of clinical trials and show tremendous potential for treatment of 
T315I+ CML.  Aurora kinase inhibitors do not bind to the threonine at 315, so they 
are not rendered ineffective in blocking the tyrosine kinase activity.  ROS-generating 
agents prevent proliferation and induce cell death by critically raising intracellular 
oxidative levels in cancerous cells.  With the wealth of scientific research and 
experimentation that has abounded regarding CML in the past 15 years, chronic 
myeloid leukemia has become a truly treatable disease. 
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